BSRBR-RA – Review of 2025!

2025 was another good year for BSRBR-RA. As always, we are very grateful to the NHS professionals who provide data, and to the participants, especially those who have completed follow up questionnaires. BSRBR-RA are proud to have had a wide impact, with results having answered many important questions. With questions still to be answered, we still need your support! 

Our year in numbers

Our publications this year

Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK.

Association between body weight and tocilizumab effectiveness in rheumatoid arthritis.

Looking forward to 2026…

This year, BSRBR-RA turns 25! We’re looking forward to celebrating 25 years of impact on the rheumatology world: watch this space for more information!

Priorities for the year:

• Recruitment of all eligible patients to the study, particularly those starting JAKi therapies.
• Follow up data collection, both from hospital sites and patient participants.
• Meeting NHS professionals at the BSR annual conference in April. If you are attending, please get in touch to arrange a catch up with us.

Again, thank you to everyone who contributes to the BSRBR-RA Study.

Happy New Year!

Related